FDA grants priority review for Takeda (TAK) and Protagonist’s rusfertide in PV treatment

Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the most promising stocks under $20. On March 2, Takeda and Protagonist Therapeutics announced that the US FDA accepted the New Drug ...
Benzinga.com

What's Going On With Takeda Stock On Friday?

On Friday, Takeda Pharmaceutical Co Ltd's (NYSE:TAK) stock wobbled after touching as low as $14.53 during the premarket session, before bouncing back to about $15.47 at last check Friday. On Thursday, ...
Yahoo Finance

Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Healthcare Stocks to Buy for 2026?

Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the best healthcare stocks to buy for 2026. Takeda Pharmaceutical Company Limited (NYSE:TAK) reported Q3 FY2025 results on January 29, 2026, ...
Business Wire

Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE: 4502/NYSE:TAK) will present today positive results from its Phase 2b trial of TAK-861 in narcolepsy type 1 (NT1) as late-breaking data ...